Low-dose naltrexone (LDN) as a novel anti-inflammatory treatment


The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.

Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.

Clin Rheumatol. 2014 Feb 15; PMID: 24526250 [PubMed – as supplied by publisher]

Authors: Younger J, Parkitny L, McLain D

Source: http://www.ncbi.nlm.nih.gov/pubmed/24526250?dopt=Abstract

Link to full free article: http://link.springer.com/article/10.1007%2Fs10067-014-2517-2/fulltext.html

Brandon Wuerth

About Brandon Wuerth

Brandon Wuerth is a resident physician in Internal Medicine at the Medical University of South Carolina in Charleston, SC. He has Crohn’s Disease and plans on pursuing Gastroenterology after completing residency in Internal Medicine. He has done clinical rotations and research with various IBD docs including Dr. Dryden (Louisville), Dr. Rubin (UChicago) and Dr. Hanauer (Northwestern).

Leave a Reply